Last reviewed · How we verify

Alexza Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Alexza Pharmaceuticals, Inc. pipeline: 2 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 3 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Inhaled loxapine 10 mg Inhaled loxapine 10 mg marketed
Placebo IM Placebo IM marketed
Inhaled Loxapine Inhaled Loxapine phase 3 Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eli Lilly and Company · 2 shared drug classes
  2. Acacia Pharma Ltd · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
  5. Alza Corporation, DE, USA · 1 shared drug class
  6. Assistance Publique Hopitaux De Marseille · 1 shared drug class
  7. Alkermes, Inc. · 1 shared drug class
  8. AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Alexza Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Alexza Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alexza-pharmaceuticals-inc. Accessed 2026-05-16.

Related